FSSAI takes legal action against Nestle India over baby food
India's food safety regulator FSSAI said on Friday it is taking legal action against Nestle India after a baby food sample failed quality standards and two infant nutrition products were promoted in breach of rules. A follow-up formula sample was found non-conforming on biotin, confirmed by a referral laboratory. FSSAI cited promotional violations for NAN Excella Pro Stage 1 and Lactogen Pro 1, filing three adjudication cases. Nestle said its products are fully compliant.
Source
Hindustan Times — India · read the original report ↗
Desk check · compared with the source
What the desk checked (5)
- FSSAI has filed three separate adjudication cases against Nestle India over three products. — Attributed to FSSAI in the source; statement repeated twice in the text.
- A follow-up formula sample was found substandard for biotin content, confirmed by a referral laboratory under the Foods for Infant Nutrition Regulations, 2020. — Directly quoted from FSSAI in the source.
- NAN Excella Pro Stage 1 and Lactogen Pro 1 violated Regulation 4(2) of the 2020 rules and Section 3 of the IMS Act, 1992. — Attributed to FSSAI with regulation references cited in the source.
- Nestle India says its products are fully compliant and that the two cited products and labels were approved by the regulator's expert committee. — Attributed to an unnamed Nestle India spokesperson; company did not address the third product.
- Milk and nutrition products generated a third of Nestle India's product sales worth $2.4 billion (Rs 23,000 crore) in the year ending March 2026. — Figure appears in the source, reported with Reuters inputs; no primary document cited.
Analysts’ view opinion
The market reaction — a near 3% drop that recovered to a flat close — suggests investors are reading this, for now, as a product-level regulatory dispute rather than a Maggi-style business disruption. But the exposure is not trivial: milk and nutrition products generated a third of Nestle India's product sales in the year ending March 2026, worth roughly ₹23,000 crore ($2.4 billion), so the dispute touches the company's most valuable franchise. In infant nutrition, the real cost is rarely the penalty amount — it is the erosion of parental trust.
- The reputational cost likely outweighs the immediate financial one, because purchase decisions in baby food turn on trust far more than on price.
- With milk and nutrition accounting for a third of product sales, even a small loss of market share would show up visibly in revenue.
- The promotional-violation charge matters commercially: tighter enforcement on labels and claims could force the whole category to rework marketing, raising compliance costs.
- Nestle's contention that the labels were cleared by the regulator's own expert committee, if borne out, points to a regulatory clarity gap — itself an uncertainty cost for the industry.
- A single sample failing on biotin does not by itself imply a systemic quality problem, but the referral lab confirming it adds pressure on quality-control spending.
What to watch — Watch the outcome of the three adjudication cases, whether any recall or label-change directive follows, and whether milk and nutrition sales growth softens in coming quarters.
The story does not establish the size of any penalty, whether a recall or sales restriction will follow, or any measurable hit to sales so far — the allegations remain to be settled.
Deep dive
Research brief · 8 facts · 5 dates · exam-readyThe brief
Context
India's food regulator, the Food Safety and Standards Authority of India (FSSAI), has initiated legal action against Nestle India after a follow-up formula sample failed quality standards on biotin content and two infant nutrition products were found to be promoted in breach of rules. Infant foods in India are governed by the FSS (Foods for Infant Nutrition) Regulations, 2020 and the Infant Milk Substitutes (IMS) Act, 1992, which bar advertising and promotion of infant milk substitutes. Nestle India says its products are fully compliant and that the labels cited were approved by the regulator's expert committee. The company has a history of run-ins with the regulator, notably the 2015 Maggi noodles ban.
Key facts
- FSSAI said on Friday it has filed three separate adjudication cases against Nestle India Ltd over three products.
- A sample of follow-up formula made by Nestle was found substandard for biotin (vitamin B7) content in laboratory analysis; a referral laboratory also found it non-conforming.
- The biotin reference range is prescribed under the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020.
- Promotional violations were cited for two products: NAN Excella Pro Stage 1 and Lactogen Pro 1.
- FSSAI invoked Regulation 4(2) of the FSS (Foods for Infant Nutrition) Regulations, 2020 and Section 3 of the IMS Act, 1992.
- Nestle India shares fell almost 3% after news of the regulatory action but recovered to close nearly flat.
- Milk and nutrition products, including infant formula and baby foods, were Nestle India's biggest revenue category in the year ending March 2026 — a third of product sales worth $2.4 billion (Rs 23,000 crore).
- In 2015, Nestle's Maggi noodles were banned over alleged excess lead levels and labelling lapses, triggering a massive recall; Maggi returned after fresh tests.
Timeline
- 1992Infant Milk Substitutes (IMS) Act enacted; Section 3 prohibits advertisement and promotion of infant milk substitutes.
- 2015Nestle's Maggi noodles banned over alleged excess lead levels and labelling lapses; massive recall followed, with return to shelves after fresh tests.
- 2020Food Safety and Standards (Foods for Infant Nutrition) Regulations notified, setting biotin reference range and restricting promotional claims.
- Year ending March 2026Milk and nutrition products become Nestle India's biggest revenue category, a third of product sales worth $2.4 billion (Rs 23,000 crore).
- Friday (date not stated in the source)FSSAI announces legal action and three adjudication cases against Nestle India; shares dip nearly 3% before closing flat.
Who has a stake
- FSSAI — Enforcing infant nutrition standards and the ban on promotion of infant milk substitutes; credibility of its testing and adjudication process.
- Nestle India Ltd — Faces three adjudication cases; says products are fully compliant and labels were approved by FSSAI's expert committee; milk and nutrition is its largest revenue category.
- Infants and parents/caregivers — Rely on accurate nutrient content (biotin) and on advertising restrictions that protect against misleading promotion of infant foods.
- Investors and shareholders — Share price volatility — stock fell almost 3% on the news before recovering to close nearly flat.
- Referral laboratory / testing labs — Re-analysis confirmed non-conformity, making lab findings central to the legal action.
Why it matters
Infant formula is often the sole source of nutrition for babies, so deviations from prescribed nutrient ranges and aggressive promotion are treated as serious regulatory breaches in India. The case tests FSSAI's enforcement of the 2020 infant nutrition regulations and the IMS Act against a market leader whose milk and nutrition business accounts for a third of its product sales. It also highlights a wider food safety push and the friction between company claims of compliance and regulator findings.
UPSC angle
Prelims pointers
- FSSAI: Food Safety and Standards Authority of India, the national food safety regulator.
- Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020: prescribe biotin range; Regulation 4(2) restricts promotional claims/material for infant foods.
- IMS Act, 1992 (Infant Milk Substitutes Act): Section 3 prohibits advertisement and promotion of infant milk substitutes.
- Biotin is commonly known as vitamin B7.
- Products named: follow-up formula (biotin non-conformity), NAN Excella Pro Stage 1 and Lactogen Pro 1 (promotional violations).
- Maggi noodles were banned in 2015 over alleged excess lead and labelling lapses before returning after fresh tests.
Mains framing
The FSSAI action against Nestle India brings together two strands of India's infant food regulation: product quality conformity and the statutory bar on promoting infant milk substitutes. On quality, a follow-up formula sample was found substandard on biotin, with a referral laboratory confirming non-conformity with the reference range set under the FSS (Foods for Infant Nutrition) Regulations, 2020 — a matter of consequence because formula may be an infant's only food. On promotion, FSSAI invoked Regulation 4(2) and Section 3 of the IMS Act, 1992 against NAN Excella Pro Stage 1 and Lactogen Pro 1, reflecting the legislative intent to insulate infant feeding choices from marketing influence. Nestle counters that the products and labels were cleared by the regulator's expert committee and that label statements are factual and backed by scientific literature, pointing to a gap between pre-approval of labels and later enforcement interpretation. Implications span consumer trust, market conduct in a segment that is Nestle India's largest revenue category, and investor sentiment. The way forward lies in clearer label-approval criteria, transparent and time-bound adjudication, robust referral-lab testing protocols, and consistent enforcement across manufacturers, alongside consumer awareness of the IMS Act's promotion ban.
Key terms
- FSSAI
- Food Safety and Standards Authority of India, the regulator that tested the sample and filed the adjudication cases.
- Follow-up formula
- A category of infant nutrition product; the Nestle sample of it failed the prescribed biotin requirement.
- Biotin (vitamin B7)
- A vitamin for which the 2020 infant nutrition regulations specify a standardized reference range in baby food.
- Regulation 4(2), FSS (Foods for Infant Nutrition) Regulations, 2020
- Provision restricting promotional claims or material meant to increase the salability of infant foods.
- IMS Act, 1992
- Infant Milk Substitutes Act; its Section 3 prohibits advertisement and promotion of infant milk substitutes.
- Adjudication case
- The legal proceeding FSSAI has filed — three in all — against Nestle India over the three products.
Practice questions
- Discuss the rationale behind India's statutory prohibition on advertising infant milk substitutes under the IMS Act, 1992, and the challenges in enforcing it.
- The FSSAI action against Nestle India reveals gaps between label pre-approval and subsequent enforcement. Examine with reference to the Foods for Infant Nutrition Regulations, 2020.
- How can food safety regulators strengthen sampling, referral-laboratory testing and adjudication to build consumer trust in infant nutrition products?
Grounded only in the source report — figures and dates are the source's, not inferred.